Literature DB >> 2764383

Antileukoprotease is associated with elastin fibers in the extracellular matrix of the human lung. An immunoelectron microscopic study.

J A Kramps1, A H Te Boekhorst, J A Fransen, L A Ginsel, J H Dijkman.   

Abstract

Human lung antileukoprotease (ALP) is a potent inhibitor of neutrophil elastase that is locally produced by submucosal bronchial glands and by secretory cells in the bronchiolar epithelium. In a recent light microscopic investigation, ALP was detected in the connective tissue matrix of the lung. The present immunoelectron microscopic study was performed in order to extend our knowledge about the exact localization of ALP in the extracellular matrix of the lung. Both elastin and ALP were detected in central and peripheral human lung specimens using specific antibodies in a two-step, gold-labeling procedure. ALP could be demonstrated in the parenchymal matrix of the alveolar walls exclusively in association with the amorphous elastin fibers. In addition, the subepithelial connective tissue of the bronchial wall also showed a clear labeling for ALP, which was present exclusively over the elastin fibers. The results of this study strongly suggest that ALP play a modulating role in destructive pulmonary diseases such as emphysema in which degradation of elastin fibers by elastase is thought to occur.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2764383     DOI: 10.1164/ajrccm/140.2.471

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  10 in total

Review 1.  Neutrophil elastase, proteinase 3, and cathepsin G as therapeutic targets in human diseases.

Authors:  Brice Korkmaz; Marshall S Horwitz; Dieter E Jenne; Francis Gauthier
Journal:  Pharmacol Rev       Date:  2010-12       Impact factor: 25.468

2.  Relation between small airways disease and parenchymal destruction in surgical lung specimens.

Authors:  L N Willems; J A Kramps; T Stijnen; P J Sterk; J J Weening; J H Dijkman
Journal:  Thorax       Date:  1990-02       Impact factor: 9.139

3.  Oxidized mucus proteinase inhibitor: a fairly potent neutrophil elastase inhibitor.

Authors:  C Boudier; J G Bieth
Journal:  Biochem J       Date:  1994-10-01       Impact factor: 3.857

4.  Pharmacological activity of the C-terminal and N-terminal domains of secretory leukoprotease inhibitor in vitro.

Authors:  K Masuda; T Kamimura; K Watanabe; T Suga; M Kanesaki; A Takeuchi; A Imaizumi; Y Suzuki
Journal:  Br J Pharmacol       Date:  1995-07       Impact factor: 8.739

5.  Potential role of recombinant secretory leucoprotease inhibitor in the prevention of neutrophil mediated matrix degradation.

Authors:  C G Llewellyn-Jones; D A Lomas; R A Stockley
Journal:  Thorax       Date:  1994-06       Impact factor: 9.139

6.  Pulmonary deposition and disappearance of aerosolised secretory leucocyte protease inhibitor.

Authors:  J Stolk; J Camps; H I Feitsma; J Hermans; J H Dijkman; E K Pauwels
Journal:  Thorax       Date:  1995-06       Impact factor: 9.139

7.  Secretory leukocyte protease inhibitor (SLPI) is, like its homologue trappin-2 (pre-elafin), a transglutaminase substrate.

Authors:  Kévin Baranger; Marie-Louise Zani; Valérie Labas; Sandrine Dallet-Choisy; Thierry Moreau
Journal:  PLoS One       Date:  2011-06-07       Impact factor: 3.240

Review 8.  The Role of Serine Proteases and Antiproteases in the Cystic Fibrosis Lung.

Authors:  Matthew S Twigg; Simon Brockbank; Philip Lowry; S Peter FitzGerald; Clifford Taggart; Sinéad Weldon
Journal:  Mediators Inflamm       Date:  2015-06-21       Impact factor: 4.711

9.  Structure basis 1/2SLPI and porcine pancreas trypsin interaction.

Authors:  Kei Fukushima; Takashi Kamimura; Midori Takimoto-Kamimura
Journal:  J Synchrotron Radiat       Date:  2013-09-29       Impact factor: 2.616

10.  Neutrophil elastase reduces secretion of secretory leukoproteinase inhibitor (SLPI) by lung epithelial cells: role of charge of the proteinase-inhibitor complex.

Authors:  Anita L Sullivan; Timothy Dafforn; Pieter S Hiemstra; Robert A Stockley
Journal:  Respir Res       Date:  2008-08-12
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.